Clinical Trials
73 trialsA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
FiREBOLT
Eli Lilly and Company
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
Catherine
Vall d'Hebron Institute of Oncology
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Dong-A ST Co., Ltd.
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
IKS014 in Advanced Solid Tumors That Express HER2
Iksuda Therapeutics Ltd.
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Zhejiang University
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech SE
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
CHANCES
Institut Paoli-Calmettes
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Boehringer Ingelheim
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma, Inc.
VISTA
Baylor College of Medicine
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Zhejiang University
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
NeoTISLEGA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
Adaptive Radiation for Abdominopelvic Metastases
Fox Chase Cancer Center
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd